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• Sixty-three primary and 21 retransplant cadaver kidney allografts were placed in 77 patients over a one-year 
period with three- to six-month follow-up. Eight primary grafts (12.7%) and six retransplants (28.6%) were lost to 
rejection. Patient mortality was 3.9%. There were no grafts lost and no deaths due to opportunistic infections. 
Renal function at 6 months after transplantation was similar in all primary transplant recipients regardless of risk 
factors, including advanced age, diabetes, or the need for postoperative dialysis. 
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R ESULTS previously reported from this cen-
ter for cadaver renal transplants performed 
during 1981 demonstrated the superiority of com-
bination cyc1osporine-prednisone therapy over 
conventional immunosuppression with azathio-
prine and steroids. I 3 Encouraged by these results, 
the resources of the general surgery division con-
centrated on expansion of the liver transplant pro-
gram with similar success during 1982 and 1983. 4 
In November 1983, we resumed a program in 
cadaveric renal transplantation on the general sur-
gery service at this center. We report here the re-
sults of the first 84 consecutive renal transplants 
performed using cyc1osporine-steroid therapy be-
tween November 15, 1983 and November 15, 
1984 with three- to six-month follow-up. 
MATERIALS AND METHODS 
Case Material 
Primary cadaveric renal transplants were performed in 63 
patients with a mean age of 45.6 ± 11.4 (SD) years (range 9 to 
68 years). Twenty-one retransplantations were performed. in-
cluding seven patients from the primary series who lost their 
first grafts within six months. There were 13 patients in the 
series with type I insulin-dependent diabetes mellitus. Addi-
tional demographic features of the patients are given in Tables 1 
and 2. 
Patients were selected for transplantation based only on the 
results of the preoperative screen for preformed antidonor cy-
totoxic antibodies. Patient selection was not based on HLA-A, 
HLA-B. or DR typing or historical panel reactive antibody 
(PRA). None of the patients received deliberate pretransplant 
transfusions. 
Operation 
Renal allografts from heart beating cadavers were harvested 
using the in-situ flush technique recently described for multiple 
organ procurements. 5 All grafts were separated immediately 
after harvesting and stored in iced Collins' solution. Grafts 
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were implanted within 18 to 30 hours after harvesting using a 
conventional method ,6 
Immunosuppression 
The rationale for combined cyclosporine-prednisone therapy 
has been previously described. I 3 Whenever possihle, patients 
received a 17.S mg/kg oral loading dose of CsA 4 to 6 hours 
prior to surgery. No further CsA was given until after surgery. 
If oral loading was not possible, 2 mg/kg intravenous CsA was 
administered over one hour intraoperatively after revascular-
ization of the graft was completed. 
Renal recipients usually resumed oral intake within 12 to 24 
hours after surgery and could be maintained on oral CsA 17.5 
mg/kg per day in two divided doses. If needed, this was supple-
mented or replaced by intravenous CsA, 2 mg/kg given two or 
three times per day. Whole blood CsA trough levels were moni-
tored daily using radioimrnune assay technique. 
Just prior to revascularization of the allograft, all patients 
received one gram of intravenous methylprednisolone. On the 
day after operation, a five-day burst of methylprednisolone or 
prednisone was begun starting at 200 mg per day, with daily 
reductions of 40 mg, until a maintenance level of 20 mg per day 
was reached. In high-risk patients, such as those with a pre-
vious history of acute allograft rejection or a high current PRA 
(> 30%). maintenance therapy was held at 30 mg per day. In 
children, the five-day cycle was begun at 100 mg per day and 
tapered to 20 mg per day. 
Adjustments in the immunosuppressive regimen are often re-
quired during convalescence. I If a graft which functioned 
promptly after surgery deteriorated, rejection was suspected. 
One gram of intravenous methylprednisolone was administered 
followed by a recycle of the steroid taper. CsA dosage was 
modified as needed to achieve adequate blood levels, but be-
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Table 1. Patient Demographics 
Age Range 
Mean Age Younger than 50 Years 
Primary grafts 
Retransplants 
Number 
63 
21 
± SO 14 Years 
45.6 ± 1.6 
34.9 ± 2.5 
cause of the acute nephrotoxic potential of CsA. there was 
usually little room for upward adjustment of this agent. 
If a graft was oliguric or anuric following surgery. the stand~ 
ard regimen was administered. If no improvement in function 
occurred within 10 to 14 days. treatment for rejection as 
described previously was begun. Downward adjustment of 
CsA dosage was frequently made during periods of severe oli~ 
guria or anuria. 
RESULTS 
Patient Survival 
There were two perioperative deaths and one 
late death. A 47-year-old diabetic with docu-
mented right coronary artery disease sustained a 
fatal intraoperative myocardial infarction. A 61-
year-old nondiabetic with a previous anteroposte-
rior resection for colorectal carcinoma died five 
weeks after operation of gastrointestinal hemor-
rhage and sepsis. 
The one late death in this series occurred from a 
myocardial infarction one month after allograft 
nephrectomy for chronic rejection at seven months 
after transplantation. The patient, a 32-year-old 
diabetic, also had a mild myocardial infarction 
several weeks after his transplant operation. 
Operative mortality in this series was two pa-
tients out of 77 (2.6%) with an overall series mor-
tality of three out of 77 (3.9%). 
Table 2. Basis of Renal Disease in 77 Patients 
Etiology 
Glomerulonephritis 
Diabetes mellitus 
Hypertensive nephrosclerosis 
Polycystic kidney disease 
Lupus nephritis 
Pyelonephritis 
Interstitial nephritis 
Gouty nephropathy 
Alport's syndrome 
Obstructive uropathy 
Focal sclerosis 
Scleroderma 
Wegener's granulomatosis 
Analgesic nephropathy 
Unknown 
No. of 
Patients 
15 
13 
11 
8 
3 
3 
3 
2 
2 
1 
12 
or Older Diabetics Male Female 
28 12 45 18 
3 16 5 
Graft Survival 
Graft survival is summarized in Table 3. Eight 
primary grafts have been lost to rejection ( 12.7 % ). 
Two grafts were lost to acute rejection (3.2 %). Six 
grafts were lost to chronic rejection (9.5 %), in-
cluding one graft lost when a patient stopped tak-
ing his CsA. Forty eight grafts (76.2 %) are func-
tioning three to six months after transplant. 
Seven patients who lost their primary grafts 
were retransplanted and four of these patients have 
functioning grafts. Fourteen additional patients re-
ceived retransplants, eight of which were success-
ful. Thus, 12 of 21 (57.1 %) retransplanted pa-
tients have functioning grafts three months (4 
patients) to six months (8 patients) after surgery. 
Renal Function 
Mean serum BUN, creatinine, CsA level, and 
CsA dose in patients with a functioning primary 
cadaver allograft are summarized in Table 4. 
There was no significant change in renal function 
as measured by BUN and creatinine in the first six 
months. At hospital discharge, mean serum 
creatinine was 2.3 ± 0.8 (SO) mg%. Six months 
after transplantation, mean serum creatinine was 
2.1 ± 0.9 (SO) mg%. 
Twenty five of the 48 successful primary trans-
plants required a mean of 13.9 ± 7.8 (SO) days of 
dialysis after surgery (Table 5). Average urine out-
put in the first 48 hours after transplantation was 
2,852 ± 2,872 (SD) mL for all 48 successful pri-
mary grafts. In patients requiring dialysis in the 
first week after surgery, the average first 48-hour 
urine output was 1,205 ± 1,220, SD mL com-
pared to an average output of 4,583 ± 2,000 (SD) 
Table 3. Graft Survival 
Grafts functioning at 
three months 
Grafts functioning at 
six months 
Total grafts functioning 
Percent graft survival 
Primary Grafts 
(N = 63) 
11 
37 
48 
76.2% 
Retransplants 
(N = 21) 
5 
7 
12 
57.1% 
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Table 4. Renal Function After Cadaveric Renal Transplantation 
Primary Grafts 
Hospital days 28.5 ± 10.7 
At hospital discharge 
BUN (mg%) 44.8 ± 20.6 
Creatinine (mg%) 2.3 ± 0.8 
CsA level (ng/mL) 920 ± 320 
Three months after transplant 
BUN (mg%) 40.7 ± 13.3 
Creatinine (mg%) 2.1 ± 0.7 
CsA level (ng/mL) 843 ± 358 
CsA dose (mg/kg/d) 8.6 ± 4.5 
Six months after transplant 
BUN (mg%) 39.6 ± 11.9 
Creatinine (mg%) 2.1 ± 0.9 
GsA level (ng/mL) 737 ± 212 
CsA dose (mg/kg/d) 6.9 ± 3.3 
Mean ± SO. 
mL in patients not requiring dialysis. Mean serum 
creatinine remained unchanged in patients with 
prompt graft function and was significantly better 
than mean serum creatinine at hospital discharge 
(P < 0.02), and at three months after transplanta-
tion (P < 0.05) in patients whose grafts had de-
layed function. However, at six months after trans-
plantation. there was no significant difference in 
mean serum creatinine based on early graft func-
tion (Table 5). 
Age Groups 
There was only one pediatric allograft recipient 
in this series. A 9-year-old boy with Alport's syn-
drome received a primary cadaver graft and re-
quired retransplantation for chronic rejection after 
five months. His second graft is functioning well 
six months after transplantation. 
Table 5. Effect of the Need for 
Postoperative Dialysis on Graft Function 
Immediate Required 
Function Dialysis 
(N ; 23) (N ; 25) 
First 48·hour urine 
output (mL) 4583 ± 2000 1205 ± 1220 
Hospital days 25.6 ± 12.0 31.2 ± 8.7 
At hospital discharge 
BUN (mg%) 39.3 ± 14.8 49.9 ± 24.0 
Creatinine (mg%) 2.0 ± 0.7 2.5 ± 0.9 
Three months after transplant 
BUN (mg%) 38.7 ± 13.9 42.5 ± 12.8 
Creatinine (mg%) 1.8 ± 0.5 2.3 ± 0.8 
Six months after transplant N ; 20 N; 17 
BUN (mg%) 39.5 ± 13.3 39.6 ± 10.4 
Creatinine (mg%) 2.0 ± 1.1 2.2 ± 0.7 
Mean ± SO. 
Range Range 
(N ; 48) Retransplants (N ; 12) 
10-53 31.8 ± 10.2 14-45 
13-148 49.7 ± 13.1 29-73 
0.9-4.3 2.7 ± 1.7 1.0-6.9 
329-1587 732 ± 239 405-1207 
21-86 46.2 ± 16.9 23-84 
1.0-4.3 2.1 ± 0.9 1.4-4.6 
359-2273 776 ± 401 130-1489 
3.0-22.0 7.2 ± 3.3 4.0-15.0 
N = 37 N = 7 
20-64 40.4 ± 10.0 29-56 
1.0-6.0 2.0 ± 0.4 1.6-2.9 
310-1241 563 ± 209 241-889 
3.0-20.0 5.1 ± 1.5 3.0-8.0 
Twenty eight patients aged 50 years or older 
(range, 50 to 68 years) received cadaver allo-
grafts. Twenty three of these patients have func-
tioning allografts (82. 1 %). Renal function for allo-
grafts in these older patients was not significantly 
different than the level of function achieved in 
younger patients (Table 6). 
GsA 
At discharge from the hospital, mean trough 
CsA blood levels in the 48 patients with function-
ing primary allografts was 920 ± 320 (SO) ng/ 
mL (Table 4). Three months after transplantation, 
mean CsA trough level was 843 ± 358 (SO)ng/ 
mL and at 6 months, 737 ± 212 (SO) ng/mL. 
Blood levels in the retransplanted patients were not 
significantly different (Table 4). Three months af-
ter transplantation, primary recipients were taking 
an average of 8.6 ± 4.5 (SO) mg/kg per day of 
CsA. At six months after transplantation, the 
Table 6. Effect of Patient Age on Graft Function 
Younger than 50 Years 
50 Years and Older 
(N ; 25) (N ; 23) 
Hospital days 28.7 ± 10.2 28.3 ± 11.3 
At hospital discharge 
BUN (mg%) 45.8 ± 25.8 43.7 ± 13.4 
Creatinine (mg%) 2.3 ± 0.8 2.3 ± 0.8 
Three months after transplant 
BUN (mg%) 40.7 ± 13.4 40.6 ± 13.5 
Creatinine (mg%) 2.1 ± 0.7 2.1 ± 0.7 
Six months after transplant N ; 21 N ; 16 
BUN (mg%) 40.6 ± 11.7 38.3 ± 12.4 
Creatinine (mg%) 2.0 ± 0.5 2.3 ± 1.3 
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average CsA dose was 6.9 ± 3.3 (SD) mg/kg per 
day. 
Hypertension, tremors, gingival hyperplasia, 
and hypertrichosis were seen to some degree in all 
patients. Hypertension was the most troublesome 
side effect and over 75 % of the patients required 
multiple drug therapy to control it. 
Significant hepatic dysfunction occurred in three 
patients. One lost his graft as a complication of 
recurrent wound hemorrhages and another lost his 
graft to renal vein thrombosis. The third patient 
improved with reduction in CsA dose and con-
tinues to have good graft function after six months. 
There have been no lymphoproliferative lesions 
in the patients in this series so far. No patients have 
been converted from CsA-prednisone therapy to 
conventional therapy with azathioprine and ste-
roids. Four allografts with steroid resistant rejec-
tion were rescued with a course of OKT-3 mono-
clonal antibody (Ortho Pharmaceutical Corp, 
Raritan, N.J.). 
Hospitalization 
The mean duration of hospital stay for the 
successful primary transplant patients was 28.5 ± 
10.7 (SD) days (Table 4). Primary recipients with 
prompt graft function required 25.6 ± 12.0 SD 
days. Those patients who required early postoper-
ative dialysis were hospitalized 31.2 ± 8.7 (SD) 
days (Table 5). Patients aged 50 years and older 
were discharged after a mean stay of 28.3 ± 11.3 
(SD) hospital days and patients younger than 50, 
after 28.7 ± 10.2 (SD) hospital days (Table 6). 
Diabetics were hospitalized 31.6 ± 9.4 (SD) days 
versus 27.8 ± 10.9 (SD) days for nondiabetics 
(Table 7). There are no significant differences 
Table 7. Effect of Diabetes on Graft Function 
Non· 
Diabetics diabetics 
Number transplanted 12 51 
Number of 
functioning grafts 9 (75.0%) 39 (76.5%) 
Hospital days 31.6 ± 9.4 27.8 ± 10.9 
At hospital discharge 
BUN (mg%) 64.3 ± 32.6 40.3 ± 13.8 
Creatinine (mgOfo) 2.8 ± 0.9 2.2 ± 0.8 
Three months after transplant 
BUN (mgOfo) 49.0 ± 16.4 38.8 ± 11.9 
Creatinine (mgOfo) 2.5 ± 1.0 2.0 ± 0.6 
Six months after transplant N = 6 N = 31 
BUN (mg%) 49.2 ± 7.0 37.7 ± 11.8 
Creatinine (mgOfo) 2.7 ± 0.6 2.0 ± 0.9 
Mean ± SO. 
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among these figures for hospital stay for any of 
these selected patient groups. 
Thirty three readmissions to the hospital in 19 
patients are summarized in Table 8. CsA toxicity 
necessitated readmission on nine occasions 
(27.3 %). Infections required eight admissions 
(24.2 %). Three patients developed late ureteral 
obstruction. One patient required intraperitoneal 
drainage of a lymphocele. Two patients required 
uretero-ureterostomy for obstruction of the graft 
ureteral implant. Two of these three grafts are still 
functioning and one was lost to chronic rejection. 
Infections 
There were 20 opportunistic infections in this 
series. Nine cases of herpes simplex or herpes zos-
ter were treated with systemic therapy. Four cases 
of cytomegalovirus infection with positive buffy 
coat, urine, or throat wash cultures were docu-
mented. Seven cases of pneumocystis carinii 
pneumonia required hospitalization, reduction in 
immunosuppressive therapy, and antibiotics. All 
patients recovered and no grafts were lost. 
Diabetes 
Thirteen of the 77 patients in this series were 
transplanted for diabetic nephropathy. Nine of 12 
primary graft recipients have a functioning kidney 
three to six months after transplantation. Two 
grafts were lost to chronic rejection within six 
months. 
Renal function in diabetic and nondiabetic pri-
mary recipients is summarized in Table 7. Mean 
serum creatinine in the diabetic recipients at hospi-
tal discharge was 2.8 ± 0.9 (SD) mg% and at 3 
months 2.5 ± 1. 0 (SD) mg %. These values are 
significantly higher than discharge creatinine (2.2 
± 0.8 [SD] mg%, P < 0.05) and 3 month 
creatinine (2.0 ± 0.6 [SD] mg%, P < 0.05) in 
the nondiabetic patients. However, at 6 months 
creatinine in diabetic recipients (2.7 ± 0.6 [SD] 
Table 8. Indications for 33 Hospital Readmissions 
No. of 
Indication 
CsA toxicity 
Infection 
Allograft rejection 
Uncontrolled diabetes 
Ureteral obstruction 
Miscellaneous medical problems 
Hypertension (without CsA toxicity) 
Patients 
9 
8 
7 
3 
3 
2 
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mg %) was not significantly different than 
creatinine in non-diabetics (2.0 ± 0.9 [SD] 
mg%). 
Two diabetics developed serious forefoot infec-
tions requiring a major amputation within 6 
months after transplantation. Both patients con-
tinue to have functioning grafts. There were no 
deep wound infections or perigraft abscesses in 
any patients. 
Gastrointestinal Complications 
Two patients developed severe postoperative 
colonic distension requiring a surgical decompres-
sion. One patient was treated with a colostomy and 
bowel continuity was restored within three weeks. 
The kidney was lost to renal vein thrombosis. A 
second patient suffered microperforations of the 
cecum requiring a limited right colon resection 
with exteriorization ofthe colon and ileum. Bowel 
continuity was restored eight weeks later. The pa-
tient's graft is functioning well. One death from 
gastrointestinal hemorrhage and sepsis was dis-
cussed previously. 
DISCUSSION 
Forty eight of 63 primary cadaver renal allo-
grafts are functioning three to six months after 
transplantation. Four of seven patients whose pri-
mary grafts failed were successfully retrans-
planted within a short interval. Even with a high 
technical loss rate (7.9 %) in the first six months of 
this series, 52 of63 (82.7%) primary patients ulti-
mately left the hospital with a functioning graft. 
Twelve of 2 I patients (57.1 %) given retrans-
plants have functioning kidneys three to six 
months after operation. Three of the six grafts lost 
to rejection were in patients with a panel reactive 
antibody in excess of 40 %. The transplant waiting 
list in Pittsburgh, as in many other centers, con-
tains a large percentage of patients with a high 
PRA. 
These results were achieved with an overall pa-
tient mortality of less than 4% and modest morbid-
ity. Diabetics are at higher risk of death from car-
diac complications than nondiabetics. We continue 
to use liberal criteria for pretransplant cardiac 
catheterization and coronary revascularization in 
diabetic candidates for kidney transplantation. 
A major advantage of CsA is the ability to use 
the drug effectively with lower doses of steroids 
than was possible with azathioprine without an in-
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creased risk of graft loss. Only six of 83 grafts 
(7.2 %) have been lost to chronic rejection despite 
maintenance doses of 10 mg prednisone per day in 
most patients within 3 months of transplantation. 
Herpes viruses, cytomegalovirus infections, and 
pneumocystis carinii pneumonia remain a threat, 
but all cases in this series were managed by re-
duced immunosuppression and appropriate anti-
biotic therapy without graft loss or mortality. 
Renal function remained stable in nearly all pa-
tient groups during the three- to six-month follow-
up period. Although the level of renal function 
early after transplantation was better in non-
diabetic than in diabetic patients, the number of 
diabetics in the series was small (13 patients) and 
the differences were not detectable six months af-
ter surgery. Neither postoperative renal dysfunc-
tion requiring dialysis nor advanced age had an 
impact on functional results after transplantation. 
The high incidence of posttransplant dysfunction 
requiring dialysis (52 %) reported here reflects the 
very strict inclusion of all patients requiring any 
dialysis in the first week after transplantation. In 
our experience, prompt renal function relates most 
directly to expeditious transfer of the graft from 
donor to recipient. Most of the kidneys trans-
planted in this series were implanted 18 to 30 
hours after in-situ perfusion. Ten kidneys im-
planted with less than 18 hours cold ischemia time 
all functioned promptly. 
CsA nephrotoxicity can produce oliguria or anu-
ria and can prolong postoperative dysfunction. We 
have been willing to accept the short-term conse-
quence, of acute CsA nephrotoxicity to minimize 
graft loss from acute rejection. However, we try to 
avoid intravenous use of CsA in the perioperative 
period whenever possible and rely instead on a 
single oral loading dose 4 to 6 hours prior to sur-
gery. During convalescence, we will reduce CsA 
dosage in the face of oliguria or anuria. 
The CsA dosages and blood levels reported here 
reflect aggressive use of the drug which has 
enabled us to achieve low rates of graft loss from 
rejection. However. two recent developments have 
led us to reconsider our current protocols for use 
of CsA and steroids. Chronic interstitial fibrosis of 
the kidney has been reported 12 to 18 months after 
cardiac transplantation7 and renal transplantationS 
and may relate to high levels of CsA given in the 
first six months. Secondly, monoclonal antilym-
phocyte antibody has been available to us in recent 
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months and was used to rescue four grafts in this 
series with steroid-resistant rejection. We now 
have a new generation of triple drug therapy with 
CsA, low-dose prednisone. and monoclonal anti-
body to replace the older triple drug regimen of 
azathioprine. high-dose prednisone, and ALG. 
During most of this series, it was our policy to 
aim for 12-hour CsA trough levels (whole blood 
RIA) between 800 and 1200 ng/mL during the first 
few months after transplantation. which required 
10 to 15 mg/kg CsA per day. Within six months of 
transplantation, patients were tapered to 5 to 8 mg/ 
kg per day with 12 hour trough levels in the 650 to 
750 ng/mL range. Mean serum creatinine levcl in 
this series at six months is around 2 mg% and may 
reflect a persistent level of nephrotoxicity. 
Presently, we are accepting postoperative 12 
hour trough levels between 600 to 750 ng/mL and 
permit levels to fall to 400 to 600 within several 
months. Monoclonal antibody offers an escape 
route for patients for whom these reduced doses of 
CsA are inadequate to prevent acute rejection. It is 
possible that further downward reductions in CsA 
will be required to reduce the risk of chronic renal 
damage. 
A few patients have been encountered who are 
exquisitely sensitive to CsA and require drastic re-
duction in dosage. Nine of the 77 patients in this 
series are being maintained on a single daily oral 
dose sufficient to maintain a 24-hour trough blood 
level of 150 ng/mL. There is little margin in these 
patients between nephrotoxicity and adequate im-
munosuppression. 
Lymphoproliferativc disorders have been re-
ported in association with CsA-prednisone 
thcrapy.9 Reduction or cessation of immunosup-
pressive therapy is the treatment of choice in this 
situation. We have not encountered any of these 
lesions in the present series as yet. 
The side effects of CsA-including hyperten-
sion, hypertrichosis, gingival hyperplasia, trem-
ors, seizures, paresthesias, and flushing-are 
common and often troublesome. However, they 
arc often easily managed by modest reductions in 
dosage. 
We continue to select patients for transplantation 
with CsA-prednisone therapy based on the results 
of the screen for specific antidonor cytotoxic anti-
body without regard for the results of HLA-A. B. 
or DR typing and without a program of deliberate 
pretransplant transfusion. The excellent results 
that can be obtained with current immunosuppres-
sive therapy do not. in our opinion. justify either a 
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more restrictive selection process based on typing 
or the risk of sensitization imposed by deliberate 
transfusion. 
Current DRG criteria for renal transplantation 
permit 24 days of hospitalization with reimburse-
ment of a little more than $17,000. We found that 
our mean hospital stay was 28 days and it is esti-
mated that hospital charges in our center are ap-
proximately $600 per day. Therefore, in this cen-
ter we are incurring an average cost of about 
$16,800 per transplant, which is in agreement with 
current DRG based financing. 
SUMMARY 
Sixty-three primary and 21 retransplant cadaver 
kidney allografts were placed in 77 patients over a 
one-year period with three- to six-month follow-
up. Eight primary grafts (12.7%) and six retrans-
plants (28.6%) were lost to rejection. Patient mor-
tality was 3.9 %. Renal function at six months after 
transplantation was similar in all primary trans-
plant recipients regardless of risk factors including 
advanced age, diabetes, or the need for postopera-
tive dialysis. There were no grafts lost and no 
deaths due to viral or pneumocystis carinii infec-
tions. Average hospital stay was 28 days at a cost 
of approximately $16,800 which is in good agree-
ment with current DRG based reimbursement. The 
availability of monoclonal antibody for graft res-
cue should permit use of lower doses of CsA to 
reduce the risk of chronic nephrotoxicity. 
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